SEC Comment Letter for Alector, Inc. (ALEC) (CIK 0001653087) (ALEC) — Dec 4, 2019

Alector, Inc. (ALEC) (CIK 0001653087)
Date: Dec. 4, 2019 · CIK: 0001653087 · Accession: 0000000000-19-016087

View on Edgar

AI Filing Summary & Sentiment

Date

December 4, 2019

Author

Not clearly detected

Form

UPLOAD

Company

Alector, Inc. (ALEC) (CIK 0001653087)

Letter

December 4, 2019 Arnon Rosenthal, Ph.D. Chief Executive Officer Alector, Inc. 131 Oyster Point Blvd. Suite 600 South San Francisco, California 94080 Re:Alector, Inc. Draft Registration Statement on Form S-1 Filed December 2, 2019 CIK No. 0001653087 Dear Dr. Rosenthal: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael E. Coke

Show Raw Text

December 4, 2019
Arnon Rosenthal, Ph.D.
Chief Executive Officer
Alector, Inc.
131 Oyster Point Blvd. Suite 600
South San Francisco, California 94080
Re:Alector, Inc.
Draft Registration Statement on Form S-1
Filed December 2, 2019
CIK No. 0001653087
Dear Dr. Rosenthal:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Chris Edwards at (202) 551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Michael E. Coke

SecProbe.io